FDA 483 - Baxter Oncology GmbH - August 27, 2024

An FDA inspection conducted at Baxter Oncology GmbH in Halle Westfalen, North-Rhine-Westphalia, from August 19-27, 2024, identified significant observations documented in a Form 483. The primary issues centered on the company"s failure to ensure the identity, strength, quality, and purity of its manufactured drug products, indicating critical deficiencies in adherence to Good Manufacturing Practices.

Key violations included inadequate aseptic process simulations that did not fully represent manufacturing conditions, an unoptimized drug product filling process with sterility assurance concerns, and a lack of evidence regarding the impact of filling line sanitization residuals on product stability. Calibration procedures for drug product track speed and assets were found lacking, and drug substance storage requirements were unclear due to conflicting labeling and storage conditions. The inspection also revealed deficient validation for sterilization processes of filling line equipment and components. Standard operating procedures were either inadequate or not consistently followed, specifically concerning cleanroom behavior, audit trail reviews for data integrity, and access control tracking. Furthermore, the facility and equipment were not adequately maintained, with observations of deteriorated sealant, light fixtures, spray devices, and unkept trolleys in the GMP warehouse, alongside an absence of a rouge management procedure.

Baxter Oncology GmbH is expected to promptly address these serious observations, which highlight systemic issues across their manufacturing controls, quality systems, and facility maintenance, to ensure full compliance with regulatory standards.